Aptus Capital Advisors LLC Buys 5,248 Shares of Stryker Corporation $SYK

Aptus Capital Advisors LLC lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 4.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 112,736 shares of the medical technology company’s stock after acquiring an additional 5,248 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Stryker were worth $41,675,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Clayton Financial Group LLC bought a new position in Stryker in the third quarter worth approximately $26,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Stryker in the 2nd quarter worth $28,000. Kilter Group LLC bought a new position in shares of Stryker during the 2nd quarter worth $29,000. Howard Hughes Medical Institute purchased a new position in shares of Stryker during the second quarter valued at $29,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Stryker in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 3.1%

Stryker stock opened at $370.07 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock has a market cap of $141.62 billion, a PE ratio of 44.06, a price-to-earnings-growth ratio of 2.23 and a beta of 0.85. The stock has a 50-day moving average of $365.25 and a two-hundred day moving average of $369.27. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.01 earnings per share. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio is presently 41.90%.

Analysts Set New Price Targets

Several research analysts have issued reports on SYK shares. Wells Fargo & Company increased their target price on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Evercore set a $390.00 price objective on shares of Stryker in a report on Monday, January 5th. Citizens Jmp upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price for the company in a report on Friday, December 19th. Finally, Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Fourteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $428.61.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.